Research programme: focal adhesion protein tyrosine kinase inhibitors - undisclosed companyAlternative Names: Protein kinase inhibitors - Poniard/Scripps Research Institute; Protein tyrosine kinase 2 inhibitors; PTK2 inhibitors
Latest Information Update: 25 Jan 2013
At a glance
- Originator The Scripps Research Institute
- Developer Unknown
- Class Small molecules
- Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer